NovaBridge Biosciences (NBP) Long-Term Deferred Tax (2018 - 2022)

NovaBridge Biosciences (NBP) has reported Long-Term Deferred Tax for 3 consecutive years, with $111.4 million the latest figure, recorded in Q4 2022.

• Quarterly Long-Term Deferred Tax rose 87.16% year-over-year to $111.4 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $111.4 million (up 87.16% YoY) and the FY2022 annual result came in at $114.9 million, up 92.99% from the prior year.
• Long-Term Deferred Tax grew to $111.4 million in Q4 2022 per NBP's latest filing, from $59.5 million in the prior quarter.
• Over the last five years, Long-Term Deferred Tax for NBP reached as high as $111.4 million in Q4 2022 and fell as low as $13.3 million in Q4 2018.
• A 3-year average of $61.4 million and a median of $59.5 million in 2021 frame the typical range for Long-Term Deferred Tax.
• The largest YoY upside for Long-Term Deferred Tax was 87.16% in 2022 against a maximum downside of 87.16% in 2022.
• Year by year, Long-Term Deferred Tax stood at $13.3 million in 2018, then jumped by 346.6% to $59.5 million in 2021, then jumped by 87.16% to $111.4 million in 2022.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $111.4 million, $59.5 million, and $13.3 million for Q4 2022, Q4 2021, and Q4 2018 respectively.